With several important conferences coming up over the next 4-6 weeks, this is a good time to focus on an emerging modality.

This is an area which is slowly starting to see more interest from various biotech and pharma companies and yet the number of permuations and formats involved to optimise performance may well stymy rapid progress.

The big question I think for many of us is will they add to and go beyond what we have already or will they simply be another way of doing the same thing?

In this latest review of some important data we explore what’s what and what’s not in the context of the current and emerging landscape…

BSB subscribers can read our latest commentary – you can either log-in or click to access.

This content is restricted to subscribers

Posted by